Clinical Trials · NCT01596504
Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 142
- Start date
- May 2012
- Locations
- 8 sites, Germany
- Primary endpoint
- Change From Baseline to Day 56 in Plasma Glucose Corrected Area Under The Plasma Concentration-Time Curve (AUC) From Time 0.5 Hours to 4.5 Hours